363 related articles for article (PubMed ID: 19494809)
1. UGT1A9 -275T>A/-2152C>T polymorphisms correlate with low MPA exposure and acute rejection in MMF/tacrolimus-treated kidney transplant patients.
van Schaik RH; van Agteren M; de Fijter JW; Hartmann A; Schmidt J; Budde K; Kuypers D; Le Meur Y; van der Werf M; Mamelok R; van Gelder T
Clin Pharmacol Ther; 2009 Sep; 86(3):319-27. PubMed ID: 19494809
[TBL] [Abstract][Full Text] [Related]
2. UGT1A9, UGT2B7, and MRP2 genotypes can predict mycophenolic acid pharmacokinetic variability in pediatric kidney transplant recipients.
Fukuda T; Goebel J; Cox S; Maseck D; Zhang K; Sherbotie JR; Ellis EN; James LP; Ward RM; Vinks AA
Ther Drug Monit; 2012 Dec; 34(6):671-9. PubMed ID: 23131697
[TBL] [Abstract][Full Text] [Related]
3. Current target ranges of mycophenolic acid exposure and drug-related adverse events: a 5-year, open-label, prospective, clinical follow-up study in renal allograft recipients.
Kuypers DR; de Jonge H; Naesens M; de Loor H; Halewijck E; Dekens M; Vanrenterghem Y
Clin Ther; 2008 Apr; 30(4):673-83. PubMed ID: 18498916
[TBL] [Abstract][Full Text] [Related]
4. The impact of UGT1A8, UGT1A9, and UGT2B7 genetic polymorphisms on the pharmacokinetic profile of mycophenolic acid after a single oral dose in healthy volunteers.
Lévesque E; Delage R; Benoit-Biancamano MO; Caron P; Bernard O; Couture F; Guillemette C
Clin Pharmacol Ther; 2007 Mar; 81(3):392-400. PubMed ID: 17339869
[TBL] [Abstract][Full Text] [Related]
5. C-440T/T-331C polymorphisms in the UGT1A9 gene affect the pharmacokinetics of mycophenolic acid in kidney transplantation.
Baldelli S; Merlini S; Perico N; Nicastri A; Cortinovis M; Gotti E; Remuzzi G; Cattaneo D
Pharmacogenomics; 2007 Sep; 8(9):1127-41. PubMed ID: 17924828
[TBL] [Abstract][Full Text] [Related]
6. AcylMPAG plasma concentrations and mycophenolic acid-related side effects in patients undergoing renal transplantation are not related to the UGT2B7-840G>A gene polymorphism.
van Agteren M; Armstrong VW; van Schaik RH; de Fijter H; Hartmann A; Zeier M; Budde K; Kuypers D; Pisarski P; Le Meur Y; van der Werf M; Mamelok RD; Oellerich M; van Gelder T
Ther Drug Monit; 2008 Aug; 30(4):439-44. PubMed ID: 18641546
[TBL] [Abstract][Full Text] [Related]
7. Comparison of mycophenolic acid pharmacokinetic parameters in kidney transplant patients within the first 3 months post-transplant.
Pawinski T; Durlik M; Szlaska I; Urbanowicz A; Majchrnak J; Gralak B
J Clin Pharm Ther; 2006 Feb; 31(1):27-34. PubMed ID: 16476117
[TBL] [Abstract][Full Text] [Related]
8. Correlation of IMPDH1 gene polymorphisms with subclinical acute rejection and mycophenolic acid exposure parameters on day 28 after renal transplantation.
Kagaya H; Miura M; Saito M; Habuchi T; Satoh S
Basic Clin Pharmacol Toxicol; 2010 Aug; 107(2):631-6. PubMed ID: 20136638
[TBL] [Abstract][Full Text] [Related]
9. Best single time points as surrogates to the tacrolimus and mycophenolic acid area under the curve in adult liver transplant patients beyond 12 months of transplantation.
Mardigyan V; Tchervenkov J; Metrakos P; Barkun J; Deschenes M; Cantarovich M
Clin Ther; 2005 Apr; 27(4):463-9. PubMed ID: 15922819
[TBL] [Abstract][Full Text] [Related]
10. Pharmacogenetic effect of the UGT polymorphisms on mycophenolate is modified by calcineurin inhibitors.
Johnson LA; Oetting WS; Basu S; Prausa S; Matas A; Jacobson PA
Eur J Clin Pharmacol; 2008 Nov; 64(11):1047-56. PubMed ID: 18568343
[TBL] [Abstract][Full Text] [Related]
11. Genetic polymorphisms in metabolic enzymes and transporters have no impact on mycophenolic acid pharmacokinetics in adult kidney transplant patients co-treated with tacrolimus: A population analysis.
Yang CL; Sheng CC; Liao GY; Su Y; Feng LJ; Xia Q; Jiao Z; Xu DJ
J Clin Pharm Ther; 2021 Dec; 46(6):1564-1575. PubMed ID: 34312870
[TBL] [Abstract][Full Text] [Related]
12. How delayed graft function impacts exposure to mycophenolic acid in patients after renal transplantation.
van Gelder T; Silva HT; de Fijter H; Budde K; Kuypers D; Mamelok RD; Armstrong VW; Oellerich M
Ther Drug Monit; 2011 Apr; 33(2):155-64. PubMed ID: 21383657
[TBL] [Abstract][Full Text] [Related]
13. The pharmacokinetics of mycophenolate mofetil in Thai kidney transplant recipients.
Jirasiritham S; Sumethkul V; Mavichak V; Na-Bangchang K
Transplant Proc; 2004 Sep; 36(7):2076-8. PubMed ID: 15518751
[TBL] [Abstract][Full Text] [Related]
14. Association of UDP-glucuronosyltransferase 1A9 (UGT1A9) gene polymorphism with kidney allograft function.
Pazik J; Ołdak M; Dąbrowski M; Lewandowski Z; Sitarek E; Podgórska M; Ważna E; Płoski R; Szmidt J; Chmura A; Durlik M; Malejczyk J
Ann Transplant; 2011; 16(4):69-73. PubMed ID: 22210424
[TBL] [Abstract][Full Text] [Related]
15. Pharmacogenetic impact of UDP-glucuronosyltransferase metabolic pathway and multidrug resistance-associated protein 2 transport pathway on mycophenolic acid in thoracic transplant recipients: an exploratory study.
Ting LS; Benoit-Biancamano MO; Bernard O; Riggs KW; Guillemette C; Ensom MH
Pharmacotherapy; 2010 Nov; 30(11):1097-108. PubMed ID: 20973683
[TBL] [Abstract][Full Text] [Related]
16. The impact of uridine diphosphate-glucuronosyltransferase 1A9 (UGT1A9) gene promoter region single-nucleotide polymorphisms T-275A and C-2152T on early mycophenolic acid dose-interval exposure in de novo renal allograft recipients.
Kuypers DR; Naesens M; Vermeire S; Vanrenterghem Y
Clin Pharmacol Ther; 2005 Oct; 78(4):351-61. PubMed ID: 16198654
[TBL] [Abstract][Full Text] [Related]
17. No pharmacokinetic interactions between mycophenolic acid and tacrolimus in renal transplant recipients.
Kagaya H; Miura M; Satoh S; Inoue K; Saito M; Inoue T; Habuchi T; Suzuki T
J Clin Pharm Ther; 2008 Apr; 33(2):193-201. PubMed ID: 18315786
[TBL] [Abstract][Full Text] [Related]
18. The pharmacokinetics of mycophenolate mofetil in renal transplant recipients receiving standard-dose or low-dose cyclosporine, low-dose tacrolimus or low-dose sirolimus: the Symphony pharmacokinetic substudy.
Grinyó JM; Ekberg H; Mamelok RD; Oppenheimer F; Sánchez-Plumed J; Gentil MA; Hernandez D; Kuypers DR; Brunet M
Nephrol Dial Transplant; 2009 Jul; 24(7):2269-76. PubMed ID: 19357111
[TBL] [Abstract][Full Text] [Related]
19. In vivo higher glucuronidation of mycophenolic acid in male than in female recipients of a cadaveric kidney allograft and under immunosuppressive therapy with mycophenolate mofetil.
Morissette P; Albert C; Busque S; St-Louis G; Vinet B
Ther Drug Monit; 2001 Oct; 23(5):520-5. PubMed ID: 11591897
[TBL] [Abstract][Full Text] [Related]
20. Influence of UGT1A7 and UGT1A9 intronic I399 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients.
Inoue K; Miura M; Satoh S; Kagaya H; Saito M; Habuchi T; Suzuki T
Ther Drug Monit; 2007 Jun; 29(3):299-304. PubMed ID: 17529886
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
